PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 10806376-9 2000 The reaction was sensitive to inhibition by the CYP2D6-selective inhibitors quinidine, quinine, lobeline and norfluoxetine, whereas chemical inhibitors selective for other CYP isoforms failed to affect the reaction. Lobeline 96-104 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 48-54 10806376-9 2000 The reaction was sensitive to inhibition by the CYP2D6-selective inhibitors quinidine, quinine, lobeline and norfluoxetine, whereas chemical inhibitors selective for other CYP isoforms failed to affect the reaction. Lobeline 96-104 cytochrome P450 family 2 subfamily D member 6 Sus scrofa 48-51 10665822-7 2000 In the presence of mecamylamine (a noncompetitive nAChR antagonist), the increase in DA content of striatal dialysate samples induced by either nicotine or lobeline was attenuated. Lobeline 156-164 cholinergic receptor nicotinic beta 1 subunit Rattus norvegicus 50-55 9648873-7 1998 These results suggest that lobeline specifically interacts with DTBZ sites on VMAT2 to inhibit DA uptake into synaptic vesicles. Lobeline 27-35 solute carrier family 18 member A2 Rattus norvegicus 78-83 10567725-5 1999 However, some of the nAChR agonists at higher concentrations (1, 1-dimethyl-4-phenylpiperazinium (DMPP) and lobeline), besides their effects on presynaptic nAChRs, are able to inhibit the uptake of NE and 5-HT into nerve terminals, thereby their transmitter releasing effects are extended in time and space. Lobeline 108-116 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 21-26 9667769-6 1998 The nAChR agonists (-)nicotine, cytisine, and (+) epibatidine reduced the radioactivity due to [11C]A-84543 in the superior colliculus by 41%, 38%, and 27%, respectively, while lobeline, which also interacts with central nAChRs, produced a 24% inhibition. Lobeline 177-185 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 4-9 9255161-11 1997 Preinjection of blocking doses of unlabeled epibatidine, (-)-nicotine, lobeline and cytisine significantly inhibited [18F]FPH binding in thalamus and superior colliculus, but not in cerebellum, whereas drugs that interact with binding sites other than acetylcholine recognition sites of nAChR (e.g., mecamylamine, scopolamine, N-methylspiperone and ketanserin) had no effect on [18F]FPH accumulation in any of the brain regions examined. Lobeline 71-79 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 287-292 29427069-3 2018 VMAT2 inhibition by the natural product, lobeline, reduced methamphetamine-evoked dopamine release, methamphetamine-induced hyperlocomotion, and methamphetamine self-administration in rats. Lobeline 41-49 solute carrier family 18 member A2 Rattus norvegicus 0-5 6502210-5 1984 The alkaloid nicotinic agonists, cytisine and lobeline, were potent inhibitors of binding, while acetylcholine in the presence of the cholinesterase inhibitor di-isopropylfluorophosphate was equipotent with (+)-nicotine. Lobeline 46-54 butyrylcholinesterase Rattus norvegicus 134-148 33897801-10 2021 Our study identified metergoline, pipercallosine, celacinnine, lobeline, cystodytin G, lycoperine A, hookerianamide J, and martefragin A as putative lead compounds against POP. Lobeline 63-71 prolyl endopeptidase Homo sapiens 172-175 8080088-5 1994 Furthermore, the O-demethylase activity in a panel of microsomes prepared from a series of human livers was significantly correlated with the immunochemically determined levels of CYP2D6 protein (r = 0.925, p < 0.001), and was inhibited (> 89%) by quinidine and lobeline. Lobeline 268-276 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 180-186 2864237-5 1985 Concomitant treatment of testicular cells with nicotinic cholinergic agonists (lobeline, nicotine, and dimethylphenylpiperazinium iodide) inhibited hCG-stimulated androgen biosynthesis in a dose-dependent fashion, with IC50 values of 3 X 10(-5), 1.7 X 10(-4), and greater than 10(-3) M, respectively. Lobeline 79-87 hypertrichosis 2 (generalised, congenital) Homo sapiens 148-151 2864237-7 1985 Lobeline (10-4) M) decreased hCG-stimulated testosterone production (50-75%) throughout the 2-day culture period; however, this inhibition was reversible upon removal of the drug. Lobeline 0-8 hypertrichosis 2 (generalised, congenital) Homo sapiens 29-32 2864237-8 1985 Lobeline also inhibited hCG-stimulated cAMP accumulation as well as testosterone production induced by cholera toxin (65% inhibition), forskolin (50% inhibition), or (Bu)2cAMP (70% inhibition). Lobeline 0-8 hypertrichosis 2 (generalised, congenital) Homo sapiens 24-27 6254051-3 1980 The half-time of decay (t((1/2))) of endplate currents (e.p.c.s) recorded at a holding potential (V(m)) of -90 mV was significantly shorter in endplates treated with lobeline (50 muM; mean t((1/2)) +/- SEM = 0.41 +/- 0.02 ms) or tubocurarine (11.4 muM; t((1/2)) = 0.64 +/- 0.04 ms) than in those treated with Mg(2+) (13 mM; t((1/2)) = 1.39 +/- 0.11 ms) or a low concentration of tubocurarine (3 muM; t((1/2)) = 0.87 +/- 0.05 ms). Lobeline 166-174 latexin Homo sapiens 179-182 6254051-3 1980 The half-time of decay (t((1/2))) of endplate currents (e.p.c.s) recorded at a holding potential (V(m)) of -90 mV was significantly shorter in endplates treated with lobeline (50 muM; mean t((1/2)) +/- SEM = 0.41 +/- 0.02 ms) or tubocurarine (11.4 muM; t((1/2)) = 0.64 +/- 0.04 ms) than in those treated with Mg(2+) (13 mM; t((1/2)) = 1.39 +/- 0.11 ms) or a low concentration of tubocurarine (3 muM; t((1/2)) = 0.87 +/- 0.05 ms). Lobeline 166-174 latexin Homo sapiens 248-251 6254051-3 1980 The half-time of decay (t((1/2))) of endplate currents (e.p.c.s) recorded at a holding potential (V(m)) of -90 mV was significantly shorter in endplates treated with lobeline (50 muM; mean t((1/2)) +/- SEM = 0.41 +/- 0.02 ms) or tubocurarine (11.4 muM; t((1/2)) = 0.64 +/- 0.04 ms) than in those treated with Mg(2+) (13 mM; t((1/2)) = 1.39 +/- 0.11 ms) or a low concentration of tubocurarine (3 muM; t((1/2)) = 0.87 +/- 0.05 ms). Lobeline 166-174 latexin Homo sapiens 248-251 6254051-4 1980 Similarly, lobeline (10 muM) shortened the t((1/2)) of untreated miniature e.p.c.s by 35%; tubocurarine, however, abolished miniature e.p.c.s at the concentration required to observe its actions on e.p.c. Lobeline 11-19 latexin Homo sapiens 24-27 6254051-7 1980 By contrast, the t((1/2))s of e.p.c.s recorded in either lobeline (50 muM) or tubocurarine (11.4 muM) were independent of voltage in the range -150 to -80 mV. Lobeline 57-65 latexin Homo sapiens 70-73 6254051-7 1980 By contrast, the t((1/2))s of e.p.c.s recorded in either lobeline (50 muM) or tubocurarine (11.4 muM) were independent of voltage in the range -150 to -80 mV. Lobeline 57-65 latexin Homo sapiens 97-100 29133786-5 2017 While either GR32a/GR59c/GR66a or GR22e/GR32a/GR66a heteromultimers are sufficient for lobeline, berberine, and denatonium detection, only GR22e/GR32a/GR66a responds to strychnine. Lobeline 87-95 Gustatory receptor 32a Drosophila melanogaster 13-18 29133786-5 2017 While either GR32a/GR59c/GR66a or GR22e/GR32a/GR66a heteromultimers are sufficient for lobeline, berberine, and denatonium detection, only GR22e/GR32a/GR66a responds to strychnine. Lobeline 87-95 Gustatory receptor 22e Drosophila melanogaster 34-39 29133786-5 2017 While either GR32a/GR59c/GR66a or GR22e/GR32a/GR66a heteromultimers are sufficient for lobeline, berberine, and denatonium detection, only GR22e/GR32a/GR66a responds to strychnine. Lobeline 87-95 Gustatory receptor 32a Drosophila melanogaster 40-45 29133786-5 2017 While either GR32a/GR59c/GR66a or GR22e/GR32a/GR66a heteromultimers are sufficient for lobeline, berberine, and denatonium detection, only GR22e/GR32a/GR66a responds to strychnine. Lobeline 87-95 Gustatory receptor 66a Drosophila melanogaster 46-51 29133786-5 2017 While either GR32a/GR59c/GR66a or GR22e/GR32a/GR66a heteromultimers are sufficient for lobeline, berberine, and denatonium detection, only GR22e/GR32a/GR66a responds to strychnine. Lobeline 87-95 Gustatory receptor 32a Drosophila melanogaster 40-45 29133786-5 2017 While either GR32a/GR59c/GR66a or GR22e/GR32a/GR66a heteromultimers are sufficient for lobeline, berberine, and denatonium detection, only GR22e/GR32a/GR66a responds to strychnine. Lobeline 87-95 Gustatory receptor 66a Drosophila melanogaster 46-51 28554528-10 2017 In contrast, repeated lobeline treatment significantly increased both BrdU- and BDNF-positive cells. Lobeline 22-30 brain derived neurotrophic factor Mus musculus 80-84 28554528-11 2017 Taken together, our results indicate that lobeline produced antidepressant-like effects, likely by targeting brain beta2-containing nAChRs, serotonergic neurotransmission, and/or hippocampal cell proliferation. Lobeline 42-50 hemoglobin, beta adult minor chain Mus musculus 115-120 25921743-5 2015 In this review, the pharmacological efficacy of nAChR ligands, such as mecamylamine, lobeline, cytisine, sazetidine-A, and others will be discussed. Lobeline 85-93 cholinergic receptor nicotinic alpha 4 subunit Homo sapiens 48-53 25636069-9 2015 Using alpha-bungarotoxin, lobeline, and dihydro-beta-erythroidine, we also could show that these effects to various degrees involve alpha7, alpha3/beta2, and alpha4/beta2 n-ChRs. Lobeline 26-34 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 132-152 25636069-9 2015 Using alpha-bungarotoxin, lobeline, and dihydro-beta-erythroidine, we also could show that these effects to various degrees involve alpha7, alpha3/beta2, and alpha4/beta2 n-ChRs. Lobeline 26-34 immunoglobulin binding protein 1 Homo sapiens 158-170 27105955-8 2016 In contrast, lobeline, the most thoroughly investigated Lobelia alkaloid, is an alpha4beta2-nicAchR antagonist, a poor free radical scavenger, and is a less potent DAT inhibitor. Lobeline 13-21 solute carrier family 6 member 3 Rattus norvegicus 164-167 26702732-4 2016 Lobeline was tested by inhibiting phosphorylation of mitogen-activated protein kinases (MAPKs), NF-kappaB and IkappaBalpha in LPS-stimulated RAW 264.7 cells. Lobeline 0-8 nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha Mus musculus 110-122 24682499-10 2014 Further, repeated treatment with lobeline or 3-(pyridine-3-yl)-cytisine decreased immobility time in the FST and reduced withdrawal-induced increased BDNF and p-CREB expression in the hippocampus. Lobeline 33-41 brain derived neurotrophic factor Mus musculus 150-154 25451721-8 2015 Lobeline (1 mg/kg) treatment prevented CUS-induced reduction in BDNF expression and cell proliferation in the hippocampus. Lobeline 0-8 brain derived neurotrophic factor Mus musculus 64-68 24682499-1 2014 RATIONALE: Evidence suggests that neuronal nicotinic acetylcholine receptor (nAChR) ligand lobeline has antidepressant-like properties. Lobeline 91-99 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 43-75 24682499-1 2014 RATIONALE: Evidence suggests that neuronal nicotinic acetylcholine receptor (nAChR) ligand lobeline has antidepressant-like properties. Lobeline 91-99 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 77-82 25451721-1 2015 We have reported that brain nicotinic acetylcholine receptor (nAChR) ligand lobeline has antidepressant-like effects in mice. Lobeline 76-84 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 28-60 25451721-1 2015 We have reported that brain nicotinic acetylcholine receptor (nAChR) ligand lobeline has antidepressant-like effects in mice. Lobeline 76-84 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 62-67 24682499-10 2014 Further, repeated treatment with lobeline or 3-(pyridine-3-yl)-cytisine decreased immobility time in the FST and reduced withdrawal-induced increased BDNF and p-CREB expression in the hippocampus. Lobeline 33-41 cAMP responsive element binding protein 1 Mus musculus 161-165 24682499-6 2014 Furthermore, we determined the effects of repeated treatment with lobeline or a selective alpha4beta2 nAChR ligand 3-(pyridine-3-yl)-cytisine on brain-derived neurotrophic factor (BDNF) and phosphorylated cAMP-responsive element binding (p-CREB) protein expression in the hippocampus. Lobeline 66-74 brain derived neurotrophic factor Mus musculus 145-178 24682499-11 2014 CONCLUSIONS: Taken together, our results indicate that lobeline attenuated nicotine withdrawal-induced depression-like behavior likely by targeting brain nAChRs, noradrenergic neurotransmission, and/or hippocampal BDNF. Lobeline 55-63 brain derived neurotrophic factor Mus musculus 214-218 24484975-4 2014 Lobeline, the major alkaloid in Lobelia inflata, potently inhibited VMAT2, methamphetamine-evoked striatal dopamine release, and methamphetamine self-administration in rats but exhibited high affinity for nicotinic acetylcholine receptors (nAChRs). Lobeline 0-8 solute carrier family 18 member A2 Rattus norvegicus 68-73 24396408-1 2014 We previously demonstrated that lobeline effectively inhibited dopamine transporter (DAT)-mediated dopamine (DA) transportation. Lobeline 32-40 solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 Mus musculus 63-83 24396408-1 2014 We previously demonstrated that lobeline effectively inhibited dopamine transporter (DAT)-mediated dopamine (DA) transportation. Lobeline 32-40 solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 Mus musculus 85-88 24396408-7 2014 In addition, TH immunostaining showed that lobeline (3 mg/kg) markedly decreased the neurotoxin-induced immunoreactivity loss in the substantia nigra and striatum. Lobeline 43-51 tyrosine hydroxylase Mus musculus 13-15 24484975-5 2014 Defunctionalized, unsaturated lobeline analog, meso-transdiene (MTD), exhibited lobeline-like in vitro pharmacology, lacked nAChR affinity, but exhibited high affinity for DAT, suggesting potential abuse liability. Lobeline 30-38 solute carrier family 6 member 3 Rattus norvegicus 172-175 23875705-0 2013 Effects of VMAT2 inhibitors lobeline and GZ-793A on methamphetamine-induced changes in dopamine release, metabolism and synthesis in vivo. Lobeline 28-36 solute carrier family 18 member A2 Rattus norvegicus 11-16 21964392-2 2011 The objective of present study was to examine anxiolytic effects of lobeline (0.04 or 0.1 mg/kg), a nAChR antagonist, in C57BL/6J mice using elevated plus-maze (EPM) and marble-burying test. Lobeline 68-76 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 100-105 23370310-1 2013 UNLABELLED: Lobeline is a potential smoking cessation drug with affinity for the alpha4beta2 nicotinic acetylcholine receptor and may inhibit the blood-brain barrier (BBB) amine transporter. Lobeline 12-20 cholinergic receptor nicotinic alpha 2 subunit Rattus norvegicus 93-125 22349182-7 2012 The nicotine-induced Cx43 downregulation functionally impaired intercellular dye transfer, which could be prevented by mecamylamine, kappa-bungarotoxin, lobeline, and dihydro-beta-erythroidine but not alpha-bungarotoxin, indicating that the nAChR subtypes alpha4beta2 and alpha3beta2 but not alpha7 are involved in signal cascade. Lobeline 153-161 gap junction protein alpha 1 Homo sapiens 21-25 22119644-3 2012 In the current study, lobeline, which interacts with proteins in dopaminergic presynaptic terminals, was evaluated for its ability to attenuate neonatal ethanol-induced locomotor hyperactivity and alterations in dopamine transporter (DAT) function in striatum and prefrontal cortex (PFC). Lobeline 22-30 solute carrier family 6 member 3 Rattus norvegicus 212-232 22119644-3 2012 In the current study, lobeline, which interacts with proteins in dopaminergic presynaptic terminals, was evaluated for its ability to attenuate neonatal ethanol-induced locomotor hyperactivity and alterations in dopamine transporter (DAT) function in striatum and prefrontal cortex (PFC). Lobeline 22-30 solute carrier family 6 member 3 Rattus norvegicus 234-237 22119644-12 2012 Thus, lobeline and methylphenidate differentially altered DAT function following neonatal ethanol exposure. Lobeline 6-14 solute carrier family 6 member 3 Rattus norvegicus 58-61 20876747-1 2011 Lobeline attenuates the behavioral effects of methamphetamine via inhibition of the vesicular monoamine transporter (VMAT2). Lobeline 0-8 solute carrier family 18 member A2 Homo sapiens 117-122 20036131-2 2010 Lobeline (1) is a potent antagonist at alpha4beta2 * nicotinic acetylcholine receptors, has moderate affinity (K(i)=5.46microM) for VMAT2, and is being investigated currently as a clinical candidate for treatment of psychostimulant abuse. Lobeline 0-8 solute carrier family 18 member A2 Rattus norvegicus 132-137 20734202-0 2010 Effects of lobeline, a nicotinic receptor ligand, on the cloned Kv1.5. Lobeline 11-19 potassium voltage-gated channel subfamily A member 5 Homo sapiens 64-69 20734202-1 2010 The goal of the present study was to examine the effects of lobeline, an agonist at nicotinic receptors, on cloned Kv channels, Kv1.5, Kv3.1, Kv4.3, and human ether-a-gogo-related gene (HERG), which are stably expressed in Chinese hamster ovary (CHO) or human embryonic kidney 293 (HEK293) cells. Lobeline 60-68 potassium voltage-gated channel subfamily H member 2 Homo sapiens 186-190 20734202-9 2010 Lobeline produced use-dependent inhibition of Kv1.5 at frequencies of 1 and 2 Hz, and slowed the recovery from inactivation. Lobeline 0-8 potassium voltage-gated channel subfamily A member 5 Homo sapiens 46-51 20734202-10 2010 Lobeline also inhibited Kv3.1, Kv4.3, and HERG in a concentration-dependent manner, with IC(50) values of 21.7, 28.2, and 0.34 muM, respectively. Lobeline 0-8 potassium voltage-gated channel subfamily C member 1 Homo sapiens 24-29 20734202-10 2010 Lobeline also inhibited Kv3.1, Kv4.3, and HERG in a concentration-dependent manner, with IC(50) values of 21.7, 28.2, and 0.34 muM, respectively. Lobeline 0-8 potassium voltage-gated channel subfamily D member 3 Homo sapiens 31-36 20734202-10 2010 Lobeline also inhibited Kv3.1, Kv4.3, and HERG in a concentration-dependent manner, with IC(50) values of 21.7, 28.2, and 0.34 muM, respectively. Lobeline 0-8 potassium voltage-gated channel subfamily H member 2 Homo sapiens 42-46 20734202-10 2010 Lobeline also inhibited Kv3.1, Kv4.3, and HERG in a concentration-dependent manner, with IC(50) values of 21.7, 28.2, and 0.34 muM, respectively. Lobeline 0-8 latexin Homo sapiens 127-130 20734202-11 2010 These results indicate that lobeline produces a concentration-, time-, voltage-, and use-dependent inhibition of Kv1.5, which can be interpreted as an open-channel block mechanism. Lobeline 28-36 potassium voltage-gated channel subfamily A member 5 Homo sapiens 113-118 19855096-2 2010 Lobeline interacts with nicotinic receptor subtypes, dopamine transporters (DATs), and vesicular monoamine transporters (VMAT2s). Lobeline 0-8 solute carrier family 18 member A2 Homo sapiens 121-126 19855096-5 2010 Compared with lobeline, the analogs exhibited greater potency inhibiting DA transporter (DAT) function. Lobeline 14-22 solute carrier family 6 member 3 Homo sapiens 73-87 19855096-5 2010 Compared with lobeline, the analogs exhibited greater potency inhibiting DA transporter (DAT) function. Lobeline 14-22 solute carrier family 6 member 3 Homo sapiens 89-92 20036131-10 2010 Thus, esterification of the lobeline molecule may be a useful structural modification for the development of lobeline analogs with improved selectivity at VMAT2. Lobeline 28-36 solute carrier family 18 member A2 Rattus norvegicus 155-160 20036131-10 2010 Thus, esterification of the lobeline molecule may be a useful structural modification for the development of lobeline analogs with improved selectivity at VMAT2. Lobeline 109-117 solute carrier family 18 member A2 Rattus norvegicus 155-160 16107155-1 2005 (-)-Lobeline (2R,6S,10S), an antagonist at nicotinic acetylcholine receptors (nAChRs), inhibits the neurochemical and behavioral effects of methamphetamine and inhibits dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) function. Lobeline 0-12 solute carrier family 6 member 3 Homo sapiens 169-189 18191815-1 2008 The mechanisms of interaction between lobeline and the dopamine transporter (DAT) or the vesicular monoamine transporter (VMAT-2) are not clear. Lobeline 38-46 solute carrier family 6 member 3 Homo sapiens 55-75 18191815-1 2008 The mechanisms of interaction between lobeline and the dopamine transporter (DAT) or the vesicular monoamine transporter (VMAT-2) are not clear. Lobeline 38-46 solute carrier family 6 member 3 Homo sapiens 77-80 18191815-3 2008 Lobeline caused release of [(3)H]dopamine to a similar extent as reserpine (VMAT-2 inhibitor), but was less efficacious than methamphetamine or dopamine. Lobeline 0-8 solute carrier family 18 member A2 Homo sapiens 76-82 18191815-5 2008 These results suggest that lobeline has unique properties at the DAT and VMAT-2 which may make it useful as a pharmacotherapeutic to treat methamphetamine abuse. Lobeline 27-35 solute carrier family 6 member 3 Homo sapiens 65-68 18191815-5 2008 These results suggest that lobeline has unique properties at the DAT and VMAT-2 which may make it useful as a pharmacotherapeutic to treat methamphetamine abuse. Lobeline 27-35 solute carrier family 18 member A2 Homo sapiens 73-79 17867559-0 2007 A novel effect of lobeline on vascular smooth muscle cell: inhibition of proliferation induced by endothelin-1. Lobeline 18-26 endothelin 1 Homo sapiens 98-110 17867559-2 2007 Lobelia chinensis Lour, a traditional Chinese herb whose active ingredient is the alkaloid lobeline, demonstrated to antagonize the bioactive effect of endothelin-1 (ET-1) and prevent the proliferation of vascular smooth muscle cells (VSMCs) in hyperlipidemic rats. Lobeline 91-99 endothelin 1 Homo sapiens 152-164 17867559-2 2007 Lobelia chinensis Lour, a traditional Chinese herb whose active ingredient is the alkaloid lobeline, demonstrated to antagonize the bioactive effect of endothelin-1 (ET-1) and prevent the proliferation of vascular smooth muscle cells (VSMCs) in hyperlipidemic rats. Lobeline 91-99 endothelin 1 Homo sapiens 166-170 17867559-3 2007 The objective of the present study was to determine the effects of lobeline on proliferation of cultured human umbilical VSMCs induced by ET-1. Lobeline 67-75 endothelin 1 Homo sapiens 138-142 19765987-8 2009 Gr33a mutant flies were impaired in avoiding all nonvolatile repellents tested, ranging from quinine to denatonium, lobeline, and caffeine. Lobeline 116-124 Gustatory receptor 33a Drosophila melanogaster 0-5 19734580-3 2009 Fluorospectorphotometer was employed to investigate the intracellular concentration of rhodamine123 to reflect the effect of lobeline on the activity of MDR-related protein P-glycoprotein (P-gp). Lobeline 125-133 ATP binding cassette subfamily B member 1 Homo sapiens 173-187 19734580-3 2009 Fluorospectorphotometer was employed to investigate the intracellular concentration of rhodamine123 to reflect the effect of lobeline on the activity of MDR-related protein P-glycoprotein (P-gp). Lobeline 125-133 ATP binding cassette subfamily B member 1 Homo sapiens 189-193 19734580-10 2009 CONCLUSION: Lobeline can reverse the MDR of MCF-7/ADM cells by inhibiting the activity of P-glycoprotein. Lobeline 12-20 ATP binding cassette subfamily B member 1 Homo sapiens 90-104 17867559-4 2007 The results showed that the increased cell numbers and enhanced [3H]thymidine incorporation induced by ET-1 were inhibited and the transition of cells from static phase (G0/G1) to DNA synthesis (S) and mitotic phase (G2/M) was held back by lobeline in a concentration-dependent manner. Lobeline 240-248 endothelin 1 Homo sapiens 103-107 17867559-8 2007 Lobeline inhibited the proliferation of human umbilical VSMCs induced by ET-1 in a dose-dependent manner and the anti-proliferative effect was involved in the reduce of increased [Ca2+]i, rather than nonspecific cytotoxicity. Lobeline 0-8 endothelin 1 Homo sapiens 73-77 16107155-1 2005 (-)-Lobeline (2R,6S,10S), an antagonist at nicotinic acetylcholine receptors (nAChRs), inhibits the neurochemical and behavioral effects of methamphetamine and inhibits dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) function. Lobeline 0-12 solute carrier family 6 member 3 Homo sapiens 191-194 16107155-1 2005 (-)-Lobeline (2R,6S,10S), an antagonist at nicotinic acetylcholine receptors (nAChRs), inhibits the neurochemical and behavioral effects of methamphetamine and inhibits dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) function. Lobeline 0-12 solute carrier family 18 member A2 Homo sapiens 233-238 16107155-6 2005 Generally, all of these analogues had lower affinities at alpha4beta2 and alpha7 nAChRs compared to lobeline, thereby increasing selectivity for VMAT2. Lobeline 100-108 solute carrier family 18 member A2 Homo sapiens 145-150 15331654-8 2005 The maintenance of hyperthermia during lobeline + METH exposure restored the effects of METH on decreases in VMAT-2 as well as dopamine and 5-HT content. Lobeline 39-47 solute carrier family 18 member A2 Rattus norvegicus 109-115 15102929-5 2004 High concentrations of lobeline induced a statistically significant release of [3H]DA from HEK-hDAT-hVMAT2 cells, but only in the absence of DHTB, suggesting an hVMAT2-mediated effect. Lobeline 23-31 solute carrier family 6 member 3 Homo sapiens 95-99 15121762-10 2004 Lobelane and ketoalkene were 5-fold more potent (Ki = 0.92 and 1.35 microM, respectively) than lobeline (Ki = 5.46 microM) in inhibiting [3H]methoxytetrabenazine binding to VMAT2 in vesicle preparations. Lobeline 95-103 solute carrier family 18 member A2 Homo sapiens 173-178 15102929-0 2004 Effects of methamphetamine and lobeline on vesicular monoamine and dopamine transporter-mediated dopamine release in a cotransfected model system. Lobeline 31-39 solute carrier family 6 member 3 Homo sapiens 67-87 15102929-5 2004 High concentrations of lobeline induced a statistically significant release of [3H]DA from HEK-hDAT-hVMAT2 cells, but only in the absence of DHTB, suggesting an hVMAT2-mediated effect. Lobeline 23-31 solute carrier family 18 member A2 Homo sapiens 100-106 15102929-5 2004 High concentrations of lobeline induced a statistically significant release of [3H]DA from HEK-hDAT-hVMAT2 cells, but only in the absence of DHTB, suggesting an hVMAT2-mediated effect. Lobeline 23-31 solute carrier family 18 member A2 Homo sapiens 161-167 11841781-11 2002 The development of lobeline and lobeline analogs with targeted selectivity at VMAT2 represents a novel class of therapeutic agents having good potential as efficacious treatments for methamphetamine abuse. Lobeline 32-40 solute carrier family 18 member A2 Rattus norvegicus 78-83 11841781-5 2002 Reevaluation of the mechanism by which lobeline alters dopamine function reveals that its primary mechanism is inhibition of dopamine uptake and promotion of dopamine release from the storage vesicles within the presynaptic terminal, via an interaction with the tetrabenazine-binding site on the vesicular monoamine transporter (VMAT2). Lobeline 39-47 solute carrier family 18 member A2 Rattus norvegicus 329-334 12604705-4 2003 Calculated apparent K(i) values for the choline transporter were 1.7 microM N-n-octyl choline, 2.2 microM N-n-hexyl choline, 27 microM N-n-decylnicotinium iodide, 31.9 microM N-n-octylpyridinium iodide, 49 microM N-n-octylnicotinium iodide (NONI), 393 microM lobeline, and >/=1000 microM N-methylnicotinium iodide. Lobeline 259-267 solute carrier family 6 member 8 Rattus norvegicus 40-59 11841781-11 2002 The development of lobeline and lobeline analogs with targeted selectivity at VMAT2 represents a novel class of therapeutic agents having good potential as efficacious treatments for methamphetamine abuse. Lobeline 19-27 solute carrier family 18 member A2 Rattus norvegicus 78-83